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Vereinigung) in Nordbaden/Germany was available for analysis, covering the total 
regional population enrolled in Statutory Health Insurance (> 2.2 million lives for years 
2003 to 2009). Linear trend analyses were performed using regression analysis with the 
growth index of the prevalence rates of MHDs as dependent variable, and a coefficient 
of determination R2> 0.57 at a significance level p< 0.05 indicating a meaningful trend 
observation. Results: Overall, MHD diagnoses remained stable at rates between 31% 
and 34% during the observation period. MHDs were diagnosed more frequently in 
females (rates 37%-43%) than in males, whereas a significant increase was observed 
in males only (from 23.5% in 2003 to 28% in 2009). Most frequently diagnosed mental 
health problems in 2009 were depressive episodes, with an overall administrative 
12-months prevalence rate of 8.3%; unspecified somatoform disorders, 4.8%; harm-
ful use of tobacco, 3.4%; neurasthenia, 2.3%; and adjustment disorders, 2.2%. Age 
and gender specific trends will be reported in detail. For example, from 2003 to 2009, 
the administrative prevalence of attention-deficit/hyperactivity disorder (ADHD) 
increased by 79% (from 0.53% in 2003 to 0.95% overall; 6-12 years, 8.0%; 13-17 years, 
4.2%; adults from 0.04% in 2003 to 0.17% in 2009). Substantial prevalence increases 
were also found for dementia (significant for males only) and for disorders due to 
substance abuse (both males and females). ConClusions: The overall prevalence 
of MHDs did not increase during the observation period. Growing numbers for some 
disorders were compensated for by decreases of others.
MENTAL HEALTH – Cost Studies
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BudgET IMPACT ANALySIS of INTroduCINg LISdExAMfETAMINE 
dIMESyLATE for THE TrEATMENT of BINgE EATINg dISordEr IN THE 
uNITEd STATES
Ágh T1, Pawaskar M2, Nagy B1, Szilberhorn L1, Vokó Z1
1Syreon Research Institute, Budapest, Hungary, 2Shire, Wayne, PA, USA
objeCtives: Lisdexamfetamine dimesylate (LDX) 50 and 70 mg demonstrated efficacy 
in terms of reduced binge eating days per week in adults with moderate to severe 
binge eating disorder (BED) in 2 randomized control trials (RCTs). This analysis aimed 
to determine the budgetary impact of introducing LDX for the treatment of BED in 
the United States (US). Methods: A 1-year budget impact analysis from a US health 
care payer’s perspective was performed. The patient population in the budget impact 
analysis was treated and diagnosed BED patients aged 18 years and older in the US. It 
was estimated that 17.5% of the budget impact patient population was treated with 
LDX in the first year of use. The base case analysis assumed a 12-week course of treat-
ment, based upon RCTs’ treatment duration. The model considered health care utiliza-
tion costs, drug costs and costs of adverse events. Inputs in the model were obtained 
from literature, trial data and an epidemiology survey. Results: Based on the inputs 
and assumptions, the total direct budgetary cost of treating BED within the adult US 
population, without LDX is estimated to be $241,699,596 over a 1-year time frame. If 
LDX were to treat 17.5% of the market, then the expected total budget would increase 
to around $242,768,676 which would be primarily due to the drug cost; however, there 
would be health care utilization costs savings of around $2,257,096. Introducing LDX 
would imply incremental average per member per year cost by $0.004. ConClusions: 
The budget impact of treating BED with LDX is modest; additional scientific evidence 
on the long-term economic burden of BED and the long-term efficacy of LDX therapy 
would help better understand the budgetary effect of LDX in BED.
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LurASIdoNE IN AduLTS wITH SCHIzoPHrENIA IN THE uK: A CoST 
CoNSEquENCE ANALySIS CoNSIdErINg CoST IMPLICATIoNS of IMProvEd 
EffICACy ANd SAfETy
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objeCtives: Lurasidone is an atypical antipsychotic with a favourable metabolic 
adverse event profile, indicated for treatment of adults with schizophrenia. The 
objective of this study was to perform an analysis of the impact of lurasidone on the 
National Health Service budget in the UK. Methods: A 3-year budget impact model 
was developed based on epidemiological estimates of total number of adults beginning 
antipsychotic therapy for schizophrenia. Costs considered included drug acquisition, 
weight gain, diabetes, and hospitalisations associated with relapse. Lurasidone 3-year 
uptake was based on projected displacement of the following atypical antipsychotics: 
olanzapine, risperidone, quetiapine and aripiprazole. Efficacy data were based on indi-
rect comparisons. Univariate sensitivity analysis was conducted to assess the impact 
of differential rates of displacement. Results: The current annual cost of schizophre-
nia in the population beginning antipsychotic therapy was approximately £17m. In 
year 1, treatment costs represented 7% of total costs; hospitalisations, weight gain and 
diabetes represented 90%, 3% and 1%, respectively. Base case uptake of lurasidone was 
assumed to be 5.5% annually. Assuming that lurasidone displaced only aripiprazole, 
lurasidone was associated with a net cumulative saving of £1.9m by year 3. Assuming 
lurasidone took market share equally from all considered atypicals, the net cumulative 
saving was £739k by year 3. In this equal displacement scenario, lurasidone uptake 
ranging from 2.5% to 11% resulted in estimated cumulative 3-year savings of £369k to 
£1.5m, respectively. ConClusions: Lurasidone was associated with cost savings in 
all scenarios. Estimates of annual budget impact ranged from cost savings of £369k to 
£1.9m. Cost savings were driven predominantly by reduced rates of hospitalisations 
associated with relapse, but also reduced costs of weight gain and diabetes.
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only on particular supportive types, particular outcomes or solely on caregivers. 
Therefore a general systematic review was conducted investigating effectiveness 
of different types of supportive strategies on at least well-being of the caregiver 
or the care-recipient. Methods: A systematic literature search was conducted 
in Web of Science and PubMed. An adapted version of the Downs and Black (1998) 
checklist was used to assess methodological quality. Results: Forty-six papers met 
inclusion criteria. Although 87% of the interventions were to some extent effective, 
methods and findings were rather inconsistent. Psychoeducational interventions 
generally lead to positive outcomes for caregivers, decrease behavioral problems 
and delay permanent institutionalization of care-recipients. Cognitive behavioral 
therapy decreases dysfunctional thoughts among caregivers, and occupational ther-
apy decreases behavioral problems among patients. In general, those interventions 
tailored on individual level generate better outcomes. Comparative research on 
respite care was very rare. ConClusions: Despite methodological inconsistency, 
supporting caregivers appears to be an effective strategy often improving well-
being of caregiver or care-recipient and resulting in additional benefits for society. 
However, there is a need for more research on the (cost)-effectiveness of respite care.
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objeCtives: To examine the patterns of drug prescription for the treatment 
of attention-deficit/hyperactivity disorders in Japanese children and adoles-
cents. Methods: We conducted a cross-sectional survey on December 1, 2013, 
on patients aged 19 or less in two national mental hospitals. Patients who were 
prescribed at least one drug for the treatment of attention-deficit/hyperactivity 
disorders (anti-ADHD drug) were analyzed. Data were extracted on gender, age, 
and types and doses of psychotropic drugs. Data on the patients’ diagnoses were 
not collected. Results: The patients included 87 males and 26 females, with a 
mean age (standard deviation) of 12.4 (2.8) years. Of these 113 patients, 70 (61.9%) 
patients received the psychostimulant OROS methylphenidate (OROS-MPH) 
only, 26 (23.0%) received atomoxetine (ATMX), a selective noradrenalin reuptake 
inhibitor only, and 17 (15.0%) received the combination OROS-MPH/ATMX therapy. 
Antipsychotics were concurrently prescribed in 51 (45.1%) patients. Mood stabilizers 
were co-prescribed in 31 (27.4%) cases. Antidepressants were co-prescribed in 8 
(7.1%) patients. Anxiolytics/hypnotics were concurrently prescribed in 23 (20.4%) 
patients. ConClusions: Nearly one-sixth of patients, aged 19 or less and treated 
with anti-ADHD drug therapy in Japanese mental hospitals, were prescribed OROS-
MPH/ATMX combination therapy. In addition, almost half of these young patients 
on anti-ADHD drugs were co-prescribed antipsychotics.
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PrEvALENCE of SLEEPINg PILLS CoNSuMPTIoN ANd ITS ASSoCIATIoN wITH 
dEPrESSIvE SyMPToMS
Kodaira K, Okuyama JH, Silva M
University of Sorocaba, Sorocaba, Brazil
objeCtives: To assess the prevalence of sleeping pills consumption among Brazilian 
adults and its association with depressive symptoms. Methods: This is an analysis 
of Brazilian National Health Survey performed in 2013. Primary outcome included 
self-reported sleeping pills use in last two weeks. We assessed five independent 
variables: number of days that sleeping pills were used; self-medication practice for 
sleeping pills; depressive symptoms (measured by the Patient Health Questionnaire 
PHQ-9 for depression); sex and age. To evaluate the association between the severity 
of depression symptoms and sleeping pills consumption we calculated prevalence 
ratio (PR) adjusted for sex and age through a Poisson regression with robust variance. 
Sensitivity analysis was performed by re-sampling technique (bootstrap). Complex 
sample design was balanced in all analysis in STATA software, version 11. Results: 
44,072 individuals were included. 62.1% were women and had a mean age of 45.6 ± 
29.7. Taking sleeping pills in the last two weeks was reported by 8.5% (95% CI: 8.0-
9.0%), of which 9.7% (95% CI: 8.2-11.3%) took without medical advice. Mean duration 
of treatment in this period was 9.9 ± 8.3 days. Depressive symptoms were reported 
as: minimal by 13.9%, minor by 5.1%, moderately severe by 2.2%, and severe major 
symptoms by 1.1%. Compared to people without depressive symptoms, the PR of 
sleeping pill use was: 3.6 (95% CI: 3.1-4.1) for minimal depressive symptoms, 5.2 
(95% IC: 4.4-6.1) for minor depressive symptoms; 6.9 (95% CI: 5.8-8.2) for moderately 
severe depressive symptoms; and 9.2 (95% CI: 7.6-11.2) for severe major depressive 
symptoms (p < 0.001 for all calculations, without changes in the sensitivity analy-
sis). ConClusions: One out of ten Brazilians took pills to induce sleep in previ-
ous two weeks, and this consumption is strongly associated with the prevalence 
of depressive symptoms. Individuals that use sleep medicines should search for 
psychiatrist aid to evaluate possible co-existence of depression.
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MENTAL HEALTH dISordEr PrEvALENCE TrENdS IN gErMANy: A 
LoNgITudINAL ANALySIS
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objeCtives: The burden of mental health disorders (MHDs) is believed to be substan-
tial and increasing, but robust data on real-life diagnosis trends are rare. The objective 
of the present analysis was to explore changes in the administrative 12-months preva-
lence rates of MHDs from 2003 to 2009 in Nordbaden, Germany. Methods: The com-
plete claims database of the organization of registered physicians (Kassenaerztliche 
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Patients were categorized according to baseline disease severity using MMSE score: 
mild (21-26), moderate (15-20), moderately severe/severe (< 15). Costs associated with 
patient and caregiver health care, patient social care and informal care were evalu-
ated using information from the Resource Use in Dementia instrument (RUD) and 
the data collection form. The primary objective was the estimation of total cost over 
the 18 months period. Total cost was estimated by applying country-specific unit 
costs. Supervision time and caregiver medical costs were excluded from the base 
case analysis. Imputation methods were used for missing cost data. Results: 419 
patients were enrolled (2010-2011) in 33 centers in France, 289 (69%) remained in the 
study at 18 months. Reasons for discontinuation were subject institutionalization 
(n= 65), death (n= 21) or other reason (n= 44). Total mean cumulative costs over the 
18-month period were estimated to be respectively 24140€ (21561-26863), 34287€ 
(30357-38939) and 44171€ (40050-48755) for mild, moderate and moderately severe/
severe patients (p< 0.001) with caregiver informal care cost accounting for approxi-
mately half of the total costs (52%, 53%, 51% respectively) (excluding supervision 
time). Mean overall monthly caregiver time increased over the 18-month period in 
each severity group, mainly driven by supervision time without significant differ-
ence between severity groups in terms of change from baseline. ConClusions: 
This longitudinal study showed that costs increase with AD severity. Informal care 
cost represents the largest part of total societal cost at each intermediate time point.
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THE ECoNoMIC BurdEN of MENTAL dISordErS IN KorEA
Lee S, Ho SH, Kim HJ
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objeCtives: In recent years, mental health problems have increased and people with 
mental disorders become more prevalent. This study aims to estimate the economic 
burden of people with mental disorders in Korea. Methods: The study evaluated the 
economic burden for people with mental disorders between 2008 and 2011 by sex and 
age. Direct and indirect costs were estimated using a prevalence based approach and 
calculated based on the four nationwide databases for people with disabilities(Korea 
National Health Insurance Corporation, the National Disability Registry of Ministry of 
Health and Welfare, the Korea National Statistical Offices’ records of cause of death, 
and National Survey on Persons with disabilities). The direct costs stem from both 
primary medical and non medical expenditures directly associated with mental dis-
orders. The indirect costs are estimated based on costs of lost productivity due to 
morbidity and premature mortality by applying a 3% of discount rate. Results: The 
results showed increases in both the prevalence of mental disorders by 1.2 times(from 
67,126 to 83,035) and total economic burden by 1.6 times(from $349.2 million to $562.6 
million) during 2008-2011. The proportions of direct costs over total economic burden 
were 89%($310.9 million) in 2008 and 91%($512.0 million) in 2011 and the proportions 
of indirect costs were 11%($38.4 million) and 9%($50.6 million) respectively. In addi-
tion, direct costs for male were 1.4 times higher than direct costs for female. The 
highest total socioeconomic costs($134.8 million~$201.4 million) were incurred by 
people aged 40-49 years. ConClusions: The prevalence and economic burden of 
mental disorders associated with direct costs increased for the years 2008 and 2011 
in Korea. These findings provide underlying evidence for mental health care improve-
ments and future studies are needed to investigate pharmacological and other social 
costs for mental disorders.
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CoSTS of MENTAL dISordErS IN PoLANd ANd THEIr CoMPLICATIoNS
Lesniowska J
Kozminski University, Warsaw, Poland
objeCtives: Mental disorders constitute a major health problem with severe com-
plications and a significant impact on quality of life.This study is the first compre-
hensive study on the direct and indirect costs of mental disorders (schizophrenia, 
bipolar affective disorder, depressive episode, recurrent depressive disorder and 
reaction to severe stress, and adjustment disorders) and associated complications in 
Poland. Methods: In order to estimate the direct medical costs of mental disorders 
and their complications, including the costs of outpatient consultation, hospitaliza-
tion, rehabilitation, and drugs, data from the National Health Fund were used with 
related etiological fraction calculus. Indirect costs embraced costs of lost productiv-
ity due to absenteeism and inability to work (handicap) caused by these diseaeses, 
and costs of lost productivity due to the premature mortality. They were calcu-
lated upon Social Insurance Institution and Central Statistic Office datasets using 
human capital method. Results: Mental disorders is a cause of significant sickness 
absence and incapacity for work and therefore is associated with a growing pro-
ductivity decline in Poland. The share of indirect costs consitute almost 70% of total 
costs and indirect costs amounted to 760 mln EUR. The highest direct costs are asso-
ciated with treatment of mental disorders-related complications. ConClusions: 
The results of this study show that indirect costs can be higher than direct costs, and 
therefore cannot be ignored in health care decision-making processes. A major part 
of the total cost of analyzed mental disordes is indirect costs caused by productivity 
losses due to absenteeism and inability to work (65%). Most of these disorders can 
be successfully treated. The use of health care resources should be planned not only 
to cut direct costs of treatment but also to consider the social impact of the disease, 
through effective treatment to minimize indirect costs.
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THE ECoNoMIC BurdEN of PHArMACEuTICALS IN PEoPLE dIAgNoSEd 
wITH dEPrESSIoN, ANxIETy-rELATEd dISordEr ANd SuBSTANCE uSE IN 
AuSTrALIA
Lee Y1, Magnus A1, Chatterton ML2, Mihalopoulos C3
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objeCtives: Mental and behavioural disorders contributed 12.9% of the total bur-
den of disease in Australia, and pharmaceuticals are recommended as treatment 
objeCtives: Atypical antipsychotic-induced weight gain and metabolic side effects 
are key contributors to discontinuations and relapses among patients with schizo-
phrenia. Current treatment guidelines in Scotland recommend aripiprazole for 
adults with schizophrenia who are at risk of weight gain. Lurasidone is an atypical 
antipsychotic associated with a favourable metabolic side effect profile. The objec-
tive of this study was to conduct a cost-utility analysis to compare lurasidone with 
aripiprazole, and a budget impact analysis of introducing lurasidone treatment to 
patients with schizophrenia in the Scottish setting. Methods: A 10-year Markov 
model, incorporating a 6-week acute phase and a maintenance phase across three 
health states (stable on treatment, stable not on treatment, and relapse), was con-
structed. Baseline risks of discontinuation and relapse were derived from lurasi-
done clinical studies. Relative efficacy was taken from indirect comparisons. Costs 
included: drug therapy; relapse; outpatient; primary and residential care. Utility 
estimates were taken from literature. The budget impact analysis considered the 
difference between the acquisition cost of lurasidone per patient per year (PPPY) 
and the acquisition costs PPPY of medicines estimated to be displaced by lurasidone, 
and assumed that the uptake rate of lurasidone would be approximately 66% of that 
seen for aripiprazole in its first five years in the UK. Results: Lurasidone yielded 
a cost saving of £3,554 and a small quality-adjusted life-year (QALY) improve-
ment compared with aripiprazole. Deterministic sensitivity analysis indicated 
that results were sensitive to relapse rates. Probabilistic sensitivity analysis sug-
gested that lurasidone had the highest expected net benefit at all willingness-to-
pay thresholds. Lurasidone acquisition cost was £1,183 PPPY; the cost of displaced 
medicines was £1,182 PPPY. Lurasidone was therefore a budget neutral treatment 
option. ConClusions: Our analyses indicate that lurasidone is a clinically and 
cost-effective treatment option, which should have limited impact on prescribing 
budgets, when compared with aripiprazole.
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PErCENTAgE PrICE vArIATIoN AMoNg ANTIdEPrESSANT drugS IN INdIAN 
MArKET: AN ECoNoMIC PErSPECTIvE
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objeCtives: To calculate the variation in the drug cost involved in the treatment of 
depression during 2013-2015. Methods: Standard Treatment Guidelines (STG), 4th 
edition were perused to understand the management of depression. Current Index 
of Medical Specialities (CIMS) Oct. – Jan. 2015 issue were used to capture the price 
of drugs. Annual cost of drug treatment and its variation was studied. Results: 
According to STG, drugs needed for the treatment of depression includes Fluoxetine 
or Sertraline or Escitalopram or Venlafaxine or Mirtazapine or Imipramine or 
Amitryptylline. If we initiate the treatment with Fluoxetine 20mg OD, then the mini-
mum and maximum cost of treatment was found to be Rs.986-1789 annually. A total 
of 81% variation was observed in its minimum and maximum cost. Likewise, if the 
treatment is initiated with Amitryptylline 75mg OD, then we observed a variation of 
190% in its minimum and maximum cost of treatment. Similarly, 127% variation was 
noted for Escitalopram 10mg OD. ConClusions: A maximum of 3 fold variation was 
noted in the minimum and maximum cost of Amitryptylline. In Indian market a huge 
price variation exist, which is needed to regulate in order to maintain uniformity.
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THE ACTuAL CoST of A “forCEd SwITCH” of PSyCHIATrIC PATIENTS To A 
NEw THErAPy: A MArKov CHAIN – MoNTE CArLo SIMuLATIoN
Anelli M, Puglisi R
Keypharma srl - Product Life Group, Milano, Italy
objeCtives: The low reimbursed price of some “typical” antipsychotics could lead 
pharmaceutical companies to withdraw them from a given market, as a consequence 
of an unfavorable cost/revenue ratio. Aim of this work was to evaluate the clinical 
and economic implications of such an occurrence, i.e. of the “forced switch” of sta-
ble psychiatric patients. Methods: A Markov model was developed to identify all 
the possible scenarios related to the transition process from chlorpromazine and 
haloperidol to quetiapine (as possible examples). To replicate the “history” of a large 
number of hypothetical individual patients, a Monte Carlo simulation was performed. 
The outcomes of the switching and their impact were assessed using the estimated 
mean frequencies of the “lost to follow-up”, “died” and “stable condition” states, plus 
the estimated overall number of visits and ADRs. Transition probabilities and costs, 
from the perspective of NHS, were taken from published literature. A sensitivity 
analysis was also performed. Results: The “work” runs were performed with 500 
cohorts of 2000 subjects each, the simulations reached convergence after 26 cycles 
(corresponding to one year). Data analysis allowed to infer that 91% of the patients 
in treatment with chlorpromazine and haloperidol would be in stable conditions 
after one year from switching to quetiapine and that the incidence of ADRs would 
be 24 for 100 patients. During the first year of treatment each patient would return 
to the prescribing physician between 2-3 times. The “once-only” direct cost of the 
transition would be 1.5 - 2.5 million euros in Italy, followed by 5-7 million per year 
for new drug costs. ConClusions: This simulation confirms that, for both patients 
and NHS, “staying” with the present therapy would represent a better and more cost 
effective solution than switching, even if a higher reimbursed price were to be granted.
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objeCtives: To describe 18-month health care resource use and costs associated 
with Alzheimer’s disease (AD) for patients and caregivers in France, stratified by AD 
severity at baseline. Methods: 18-month, prospective, multi-center, cohort study 
conducted in France, Germany and UK. Enrolled outpatients were > 55 years, diag-
nosed with probable AD (NINCDS-ADRDA) and had an informal caregiver available. 
